Literature DB >> 3539199

T-cell responses at the host: tumour interface.

R A Robins.   

Abstract

The evidence considered here reinforces the conclusion that T-cell responses to tumours involve complex cellular interactions. An attempt to summarize some of these interactions is shown. This emphasizes that not only are the interactions between the effector cell populations complicated, but that the target cell surface is also subject to variation and modification as a result of the immune response. A feature that also emerges from these studies is that most cells apparently responding to or infiltrating a tumour do not necessarily participate in its destruction, and it is in this area that experimental tumour systems have particular value. This also perhaps explains the preoccupation of experimentalists with the identification of 'the' effector cell crucial to tumour rejection. However, there is heterogeneity between systems in terms of the type of rejection response induced, but a logical basis for this heterogeneity is not established. If experimental studies could define the nature of the immune response generated by a tumour in the context of the biological features of the tumour itself, this could lead to the prediction of the immunogenicity and potential for induction of a rejection response for that tumor. Clearly, experimental tumour systems do not provide an exact reflection of the situation with human tumours. However, they may provide systems that illuminate particular aspects of the human response, and give precedents to guide the interpretation of data derived from human systems. This form of assessment is still at an early stage, but developments in the experimental field should provide a framework for the development and exploitation of T-cell responses to tumours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539199     DOI: 10.1016/0304-419x(86)90019-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Authors:  Shanjin Cao; Zhaoying Xiang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2004-10       Impact factor: 11.530

3.  The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

Authors:  F Gallo; M C Morale; D Sambataro; Z Farinella; U Scapagnini; B Marchetti
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

Review 4.  Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.

Authors:  Charles Maxwell-Armstrong
Journal:  Ann R Coll Surg Engl       Date:  2002-09       Impact factor: 1.891

5.  Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques.

Authors:  Brendon J Coventry; Michael J Weightman; John Bradley; John M Skinner
Journal:  JRSM Open       Date:  2015-09-22

6.  Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression.

Authors:  L G Durrant; K C Ballantyne; N C Armitage; R A Robins; R Marksman; J D Hardcastle; R W Baldwin
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.